Skip to content

Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)

Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05127057
Acronym
PRIME-RCT
Enrollment
214
Registered
2021-11-19
Start date
2022-10-28
Completion date
2025-06-12
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism

Keywords

Lewy body dementia, Idiopathic Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal degeneration, Vascular dementia

Brief summary

People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life. Symptoms emerge and evolve as the disease progresses. Current care models are often inadequate to meet their needs. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care.

Detailed description

Background: People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life and can lead to an increased risk of hospitalisation. It is increasingly recognised that the current care models are not suitable for the needs of people with parkinsonism whose care needs evolve and change as the disease progresses. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care. Methods: This is a single centre, randomised controlled trial where people with parkinsonism and their informal caregivers are randomised into one of two groups: either PRIME Parkinson multi-component model of care; or usual care. Adults ≥18 years with a diagnosis of parkinsonism, able to provide informed consent or the availability of a close friend or relative to act as a personal consultee if capacity to do so is absent, and living in the trial geographical area are eligible. Up to three caregivers per patient can also take part, must be ≥18 years, provide informal, unpaid care and able to give informed consent. The primary outcome measure is goal attainment, as measured using the Bangor Goal Setting Interview. The duration of enrolment is 24 months. The total recruitment target is n=214 and the main analyses will be intention to treat. Discussion: This trial tests whether a novel model of care improves health and disease-related metrics including goal attainment, and decreases hospitalisations whilst being more cost-effective than the current usual care. Subject to successful implementation of this intervention within one centre, the PRIME Parkinson model of care could then be evaluated within a cluster-randomised trial at multiple centres.

Interventions

OTHERPRIME Parkinson Care

A novel model of care

OTHERUsual Care

Usual NHS Care

Sponsors

Radboud University Medical Center
CollaboratorOTHER
University of Bristol
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Have a diagnosis of parkinsonism made by a movement disorder specialist 2. Be willing to participate 3. Have the ability to provide informed consent to participant, or where unable to do so due to cognitive impairment, availability of a close friend or relative to act as a personal consultee 4. Age 18 years and above. 5. Resident within the geographical catchment area of Royal United Hospital Bath NHS Foundation Trust, UK

Exclusion criteria

1. Patients with drug, infection or toxin induced parkinsonism 2. Patients who lack capacity to participate but do not have anyone who can be a consultee to provide advice regarding the patient's wishes and views 3. Patients with a current medical, cognitive or psychosocial issue or co-enrolment in other study that, in the opinion of the site investigator, would interfere with adherence to study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Goal attainment24 monthsMeasured using the Bangor Goal-Setting Interview (BGSI) - score 1-10, higher score = better outcome

Secondary

MeasureTime frameDescription
Parkinson's disease assessment24 monthsMeasured using MDS-Unified Parkinson's disease Rating Scale (MDS-UPDRS) Score range 0-199, higher score = worse outcome
Non-motor symptom burden24 monthsMeasured using MDS-Non-motor rating scale (MDS-NMS); Score range 0-334, higher score = worse outcome
Parkinson's-related quality of life24 monthsMeasured using The Parkinson's Disease Questionnaire (PDQ-39); Score range 0-100, higher score = worse outcome
Fear of falling24 monthsMeasured using the Iconographical Falls Efficacy Scale (ICON-FES); Score range 10-40, higher score = worse outcome
Global Impression of change24 monthsMeasured using the Patients' Global Impression of Change (PGIC);Score range 0-7, higher score = worse outcome
Frailty24 monthsMeasured using The Frailty Instrument of the Survey of Health, Ageing and Retirement in Europe (SHARE-FI75+); Score range 0-1, higher score = worse outcome. Measured using Measured using Pictorial fit frail scale; Score range 0-43, higher score = worse outcome. Measured using clinical frailty scale; Score range 0-9, higher score = worse outcome
Sarcopenia24 monthsMeasured using the Sluggishness, Assistance in walking, rising from a chair, climb stairs, falls questionnaire (SARC-F); Score range 0-10, higher score = worse outcome
Malnutrition risk24 monthsMeasured using the Malnutrition Universal Screening Tool (MUST); Score range 0-6, higher score = worse outcome. Measured using the Seniors in the community: risk evaluation for eating and nutrition (SCREEN-II-14); Score range 0-64, higher score = better outcome.
Physical performance24 monthsMeasured using the Short Physical Performance Battery (SPPB); Score range 0-12, higher score = better outcome. Measured using the Timed up and Go (TUG); score is not a scale (timing).
Physical activity24 monthsMeasured using the Incidental and Planned Exercise Questionnaire - WA Version (IPEQ-WA); Score range 0-182, higher score = better outcome
Gait24 monthsMeasured using single and dual task gait assessments
Grip strength24 monthsMeasured using hand-held dynamometer; scoring is in kg not a scale
Advance Care Plan data24 monthsMeasured using the Edmonton Symptom Assessment System - Revised: Parkinson's disease (ESAS-R-PD); Score range 0-100, higher score = worse outcome
Palliative symptom burden24 monthsMeasured using the Palliative Case Outcome Scale - symptom list: Parkinson's disease (POS-S-PD); Score range 0-40, higher score = worse outcome
Hospice utilisation outside place of death24 monthsCaptured from hospital and GP records
Use of anticipatory medication24 monthsCaptured from hospital and GP records
Healthcare contacts with hospice and/or palliative care services24 monthsCaptured from hospital and GP records
Social participation24 monthsMeasured using the English Longitudinal Study of Ageing questionnaire (ELSA) - scoring not a scale
Perceived social support24 monthsMeasured using Multidimensional scale of perceived social support (MSPSS); Score range 12-84, higher score = better outcome
Coping strategy24 monthsMeasured using the Brief Coping Orientation to Problems Experienced Inventory (BRIEFCope); Score range 28-112, higher score = better outcome
Acceptance of illness24 monthsMeasured using Acceptance of Illness Scale; Score range 8-40, higher score = better outcome
Capability24 monthsMeasured using the ICEpop Capability measure for older people (ICECAP-O); Score range 5-20, higher score = better outcome
Patient Activation24 monthsMeasured using Patient Activation Measure (PAM); Score range 0-100, higher score = better outcome
Health related quality of life24 monthsMeasured using EuroQol 5D-5L (EQ-5D-5L); Score range 5-25, higher score = worse outcome
Mortality24 monthsCaptured from hospital and GP records
Healthcare events24 monthsCaptured from hospital and GP records
Frequency of Parkinson's follow-up24 monthsCaptured from hospital and GP records
Frequency and type of engagement with PRIME Parkinson care24 monthsCaptured from study information
Experience of holistic patient-centred care24 monthsMeasured using Patient Assessment of Chronic Illness Care (PACIC-26); Score range 26-130, higher score = better outcome
Montreal Cognitive Assessment24 monthsMeasured using Montreal Cognitive Assessment
Bone health24 monthsMeasured using a combination of QFracture and FRAX questionnaires
Life space assessment24 monthsMeasured using LSA questionnaire collecting participant's movements over the last month
Loneliness/social isolation24 monthsMeasured using UCLA-Loneliness Scale (3-item); Score range 3-9, higher score = worse outcome

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026